3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Other
2
Classical hematology
2
Conditions
Multiple Myeloma
3
Mucositis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Febrile Neutropenia
2
Polycystic Ovary Syndrome
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Inflammation
1
Hematologic Neoplasms
1
Early Stage Triple Negative ER Low Breast Cancer
1
Disease Progression
1
Cytokine Release Syndrome
1
Colorectal Neoplasms
1
Burkitt Lymphoma
1
Arthritis, Rheumatoid
1
Interventions
Cisplatin
4
angiotensin I (1-7)
3
Radiotherapy
3
Radiation
3
Injections
3
Water
2
RRx-001
2
Interleukin 1 Receptor Antagonist Protein
2
Drug Therapy
2
Amifostine
2
tempol
1
peppermint oil
1
pegfilgrastim
1
kang-lai-te
1
hydrated silica gel-based toothpaste
1
golotimod
1
glucarpidase
1
fish oil triglycerides
1
calcium phosphate
1
brilacidin
1
anise oil
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Xylitol
1
Vaccinium myrtillus extract
1
Tramadol
1
Therapeutics
1
Surgical Procedures, Operative
1
Sorbic Acid
1
Sodium Bicarbonate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Mucositis
×
Interleukin 1 Receptor Antagonist Protein
×
Clear all
NCT03233776
2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2
Completed
9 enrolled
NCT04099901
2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2
Completed
88 enrolled